Published Date : Feb 16, 2016
Albany, New York, Feb 16, 2016: MarketResearchReports.biz, a leading database of business intelligence reports, has announced that it now offers a report on the state of breast cancer therapeutics in key developed markets. The report is titled, ‘Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence.’ The prevalence of breast cancer has been on the rise worldwide, and this malignant neoplasm represents 16% of all cancers affecting women. However, although more women are now diagnosed with breast cancer, the death rate has declined thanks to the availability of better diagnosis and treatment options.
The eight developed regional markets that the report focuses on are: the US, Canada, France, the UK, Germany, Spain, Italy, and Japan. The report states that through the forecasting horizon, the breast cancer therapeutics market will increase in value from US$10.4 bn in 2014 to surpass US$17.2 bn by 2021 at a CAGR of 7.3%.
Targeted therapies have revolutionized the breast cancer therapeutics market, which has gathered pace over the last four years. As a result, the breast cancer therapeutics market now features an array of treatment options, ranging from chemotherapy to hormonal therapy and from combination to targeted therapies. Despite this abundance of treatment options, there still remain considerable white spaces in the global breast cancer therapeutics market as survival rate still needs improvement.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/536328
The report studies every important facet of the global breast cancer therapeutics market to lay the opportunities, threats, and trends bare. According to the report, the breast cancer therapeutics market currently comprises novel products of which the key ones are: Perjeta (targeted therapy), Halaven (novel chemotherapeutic agent), and Kadcyla (human antibody-drug conjugate).
Currently, the market is reported to have over 700 active molecules in the pipeline. Of these, the majority are undergoing evaluation and trials for first- or second-line treatment for breast cancer patients that are at an advanced stage of the diseases. The other notable aspect of the current pipeline is that it features some promising immunotherapies and new combination therapies besides chemotherapy drug candidates.
The report also cites data findings taken from previous studies to create a realistic picture about the potential of the existing pipeline drugs to fill gaps within the breast cancer therapeutics market in developed countries. The authors of the report have analyzed data drawn from clinical trials since 2006, based on which they state that the failure rate of breast cancer molecules failing was the highest during the second phase of trials. The overall attrition rate of breast cancer therapeutics is surprisingly high at 61%.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com